NPC Conference to Address Questions on Ability to Share Health Research Findings Health

NPC logo

(Washington, DC, February 6, 2012)--To examine key issues around asymmetries, or inequalities, in communicating health information coming from the growing body of comparative effectiveness research (CER), the National Pharmaceutical Council, the National Health Council and WellPoint are sponsoring a conference, Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making.

With billions of dollars in funding being invested in comparative effectiveness research, patients, providers, payers and other health care decision-makers will have more information than ever before about the safety and effectiveness of treatment options. However, not all stakeholders have equal ability to share information in the current regulatory environment. The conference will facilitate discussion about the information needs of patients, payers and other stakeholders, and how the First Amendment and other legal issues apply. Presenters will share with attendees a proposed ethical framework for communicating CER information.

Confirmed speakers include:

  • Arthur Caplan, PhD, Director, Center for Bioethics, University of Pennsylvania
  • Susan Dentzer, Editor-in-Chief, Health Affairs/Project HOPE
  • Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council
  • Scott Gottlieb, MD, Resident Fellow, American Enterprise Institute
  • Stephen Hume, PsyD, Alzheimer’s patient representative, and his care partner, Candace Darcy
  • Aaron S. Kesselheim, MD, JD, MPH, Assistant Professor of Medicine, Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital
  • Joshua D. Lenchus, DO, RPh, FACP, Associate Director, University of Miami-Jackson Memorial Hospital Center for Patient Safety, and Associate Professor of Medicine, University of Miami Miller School of Medicine
  • Gerald F. Masoudi, Partner, Covington & Burling LLP
  • Steven J. Romano, MD, Senior Vice President, Head, Medicines Development Group, Primary Care Business, Pfizer Inc
  • Robert J. Temple, MD, Deputy Center Director for Clinical Science, U.S. Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research, and Acting Deputy Director of the FDA’s Office of Drug Evaluation I
  • Tevi Troy, PhD, Senior Fellow, Hudson Institute, and former Deputy Secretary, U.S. Department of Health and Human Services
  • Marcus Wilson, PharmD, President, HealthCore

The conference will be held on Thursday, February 9, 2012, from 9:30 a.m. to 4:30 p.m. at the Omni Shoreham Hotel, 2500 Calvert St. NW, in Washington, D.C. The conference will open at 8:30 a.m. for registration and a continental breakfast.

Registration is complimentary.

To join the conversation on Twitter, use the hashtag #asym12.

# # #